- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
30 result(s) found for: Synovial fluid.
Displaying page 1 of 2.
EudraCT Number: 2018-002245-11 | Sponsor Protocol Number: NAM2 | Start Date*: 2019-01-16 |
Sponsor Name:UMC Utrecht | ||
Full Title: Assessing penetration of high dose Nicotinamide (Vitamin B3) in synovial fluid | ||
Medical condition: Juvenile Idiopathic Arthritis (JIA) | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000379-18 | Sponsor Protocol Number: 1.0 | Start Date*: 2012-05-04 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Plasma and synovial fluid pharmacokinetics of cefuroxime and linezolid in patients undergoing elective knee arthroscopy after a single intravenous dose of cefuroxime and linezolid: an exploratory m... | ||
Medical condition: Subjects under general anaesthesia after a knee surgery get a microdialysis probe insertio into the operated knee and a probe insertion into the thigh on the contralateral side. After the operation... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001428-38 | Sponsor Protocol Number: RRK2939 | Start Date*: 2006-09-18 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy | ||
Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001411-71 | Sponsor Protocol Number: R475-OA-1815 | Start Date*: 2018-12-03 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: Study to Evaluate Synovial Fluid in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip | |||||||||||||
Medical condition: Pain due to osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001501-13 | Sponsor Protocol Number: GS PSPK2 | Start Date*: 2007-07-31 | |||||||||||
Sponsor Name:ROTTAPHARM / ROTTA RESEARCH LABORATORIUM | |||||||||||||
Full Title: An open, randomized study to investigate the plasma and synovial fluid concentrations of glucosamine before and after repeated doses of crystalline glucosamine sulfate administered as oral soluble ... | |||||||||||||
Medical condition: Joint disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003059-20 | Sponsor Protocol Number: EMR700692_006 | Start Date*: 2013-07-31 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with p... | |||||||||||||
Medical condition: Primary osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006075-75 | Sponsor Protocol Number: AK106 II-01 | Start Date*: 2009-04-22 | |||||||||||
Sponsor Name:Asahi Kasei Pharma Corporation | |||||||||||||
Full Title: A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002717-19 | Sponsor Protocol Number: OLT1177-08 | Start Date*: 2023-03-20 | |||||||||||
Sponsor Name:Olatec Therapeutics LLC | |||||||||||||
Full Title: A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare | |||||||||||||
Medical condition: Treatment of Acute Gout Flare | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002963-92 | Sponsor Protocol Number: CLRX712A12201 | Start Date*: 2020-02-05 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, placebo-controlled, subject and investigator blinded study investigating the safety, tolerability and preliminary efficacy of 8-week treatment with intra-articular LRX712 to regenerat... | |||||||||||||
Medical condition: Cartilage injuries | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000101-28 | Sponsor Protocol Number: AMB-051-07 | Start Date*: 2022-12-08 | |||||||||||
Sponsor Name:AmMax Bio, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects w... | |||||||||||||
Medical condition: Tenosynovial Giant Cell Tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) IT (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003418-28 | Sponsor Protocol Number: CLNA043X2201 | Start Date*: 2017-04-18 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in ... | |||||||||||||
Medical condition: Acute cartilage injuries | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003940-30 | Sponsor Protocol Number: NO21157 | Start Date*: 2008-05-14 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarc... | |||||||||||||
Medical condition: Ewing’s sarcoma and other sarcoma subtypes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000538-31 | Sponsor Protocol Number: Neuroimpa2015 | Start Date*: 2015-06-01 | |||||||||||
Sponsor Name:Charité University medicine Berlin | |||||||||||||
Full Title: NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint | |||||||||||||
Medical condition: chronic arthritis of the knee joint effusion as part of spondyloarthritis (Assessments in SpondyloArthritis international Society, ASAS criteria), Rheumatoid Arthritis, RA (according to American Co... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004179-38 | Sponsor Protocol Number: PULMORA | Start Date*: 2020-01-10 | |||||||||||
Sponsor Name:Västra Götalandsregionen | |||||||||||||
Full Title: Effects of tofacitinib vs methotrexate on clinical and molecular disease activity markers in joints and lungs in early rheumatoid arthritis | |||||||||||||
Medical condition: Patients with early active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017306-36 | Sponsor Protocol Number: TIGER | Start Date*: 2010-11-19 | |||||||||||
Sponsor Name:Leiden University Medical Center, Department of Rheumatology | |||||||||||||
Full Title: ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA. | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000889-38 | Sponsor Protocol Number: 2019/MyJIA | Start Date*: 2020-09-16 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocortico... | ||
Medical condition: Juvenile idiopathic arthritis is characterised by inflamed joints and is the most common chronic rheumatic disease in childhood and adolescence that potentially lead to disability due to joint dama... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002126-36 | Sponsor Protocol Number: BP39261 | Start Date*: 2017-03-01 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multi-center, three-part phase II study to evaluate the safety and efficacy of RO7123520 as adjunct treatment in patients with moderately to severely... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002673-35 | Sponsor Protocol Number: Fos.06/2016 | Start Date*: 2017-03-29 |
Sponsor Name:PRO-IMPLANT Foundation | ||
Full Title: Efficacy and safety of intravenous fosfomycin in prosthetic joint infection (PJI) caused by staphylococci, streptococci, enterococci and gram-negative bacilli, including mixed infections and cultur... | ||
Medical condition: Prosthetic joint infection of knee, hip or shoulder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003631-21 | Sponsor Protocol Number: CLNA043A12203 | Start Date*: 2021-06-28 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab follow... | |||||||||||||
Medical condition: osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015810-23 | Sponsor Protocol Number: RR09/9046 | Start Date*: 2010-02-22 |
Sponsor Name:University of Leeds | ||
Full Title: Intra-articular and intravenous infliximab in the treatment of resistant seronegative oligoarthritis of the knee | ||
Medical condition: Seronegative oligoarthritis (inflammatory arthritis of 4 active joints or less) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
